Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 8—August 2004
Research

Antimicrobial Drug Use and Methicillin-resistant Staphylococcus aureus, Aberdeen, 1996–2000

Dominique L. Monnet*, Fiona M. MacKenzie†Comments to Author , José María López-Lozano‡, Arielle Beyaert§, Máximo Camacho§, Rachel Wilson†, David Stuart†, and Ian M. Gould†
Author affiliations: *Statens Serum Institut, Copenhagen, Denmark; †Aberdeen Royal Infirmary, Aberdeen, Scotland; ‡Hospital Vega Baja, Orihuela (Alicante), Spain; §University of Murcia, Murcia, Spain

Main Article

Table 1

Antimicrobial drug coresistance in methicillin-resistant Staphylococcus aureus (MRSA) isolates and in methicillin-susceptible S. aureus (MSSA), Aberdeen Royal Infirmary, 1997–2000

Antimicrobial drug MRSA isolates
MSSA isolates
Risk ratio p value
No. tested for coresistance No. resistant (%) No. tested for coresistance No. resistant (%)
Ciprofloxacin
1,218
1,195 (98.1)
515
183 (35.5)
13.4
< 0.0001
Clindamycin
2,722
2,666 (97.9)
7,715
956 (12.4)
89.6
< 0.0001
Erythromycin
2,721
2,669 (98.1)
7,701
1,115 (14.5)
90.0
< 0.0001
Fusidic acid
2,736
36 (1.3)
7,798
636 (8.2)
0.20
< 0.0001
Gentamicin
1,350
11 (0.8)
3,276
44 (1.3)
0.68
NSa
Mupirocin
2,514
154 (6.1)
5,180
99 (1.9)
1.92
< 0.0001
Rifampin
1,005
62 (6.2)
72
8 (11.1)
0.95
NS
Tetracycline
997
109 (10.9)
468
94 (20.1)
0.76
< 0.0001
Trimethoprim 1,060 18 (1.7) 0

aNS, nonsignificant.

Main Article

Page created: March 01, 2011
Page updated: March 01, 2011
Page reviewed: March 01, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external